Journey Medical (DERM) Income from Continuing Operations (2020 - 2026)
Journey Medical's (DERM) quarterly Income from Continuing Operations came in at 2230000.0 in Q1 2026, up 45.25% YoY from 1535292.43 in Q1 2025, and down 81.45% on a QoQ basis from 1229000.0 in Q4 2025.
Journey Medical (DERM) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Journey Medical (DERM) has 7 years of Income from Continuing Operations data on file, last reported at 2230000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 45.25% year-over-year to 2230000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9570000.0 (down 16.11% YoY) and the FY2025 annual result came in at 11413000.0, up 22.21% from the prior year.
- Income from Continuing Operations retreated to 2230000.0 in Q1 2026, from 1229000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 16789000.0 in Q3 2023 to a low of 10642000.0 in Q4 2022.
- A 5-year average of 3631470.59 and a median of 3361000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 266.56% in 2023, down 635.56% in 2023.
- Tracing DERM's Income from Continuing Operations over 5 years: stood at 10642000.0 in 2022, then jumped by 79.86% to 2143000.0 in 2023, then jumped by 173.82% to 1582000.0 in 2024, then slumped by 177.69% to 1229000.0 in 2025, then slumped by 81.45% to 2230000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2230000.0 (Q1 2026), 1229000.0 (Q4 2025), and 2315000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Journey Medical | 211.01 Mn | 185.37 Mn | 12.37 Mn | -312,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -312,000.00 |
| Mar 31, 2026 | -2.23 Mn |
| Dec 31, 2025 | -1.23 Mn |
| Sep 30, 2025 | -2.32 Mn |
| Jun 30, 2025 | -3.80 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Dec 31, 2024 | 1.58 Mn |
| Sep 30, 2024 | -2.39 Mn |
| Jun 30, 2024 | -3.36 Mn |
| Mar 31, 2024 | -10.44 Mn |
| Dec 31, 2023 | -2.14 Mn |
| Sep 30, 2023 | 16.79 Mn |
| Jun 30, 2023 | -8.36 Mn |
| Mar 31, 2023 | -10.14 Mn |
| Dec 31, 2022 | -10.64 Mn |
| Sep 30, 2022 | -10.08 Mn |
| Jun 30, 2022 | -7.53 Mn |
| Mar 31, 2022 | -1.38 Mn |
| Dec 31, 2021 | -21.75 Mn |
| Sep 30, 2021 | -10.65 Mn |